AICDA and myeloid sarcoma: These regions are ‘hotspots’ of interactions between genetic and nongenetic modifier of MS risk/protection: all four proteins (VDR, AID, EBNA2, EBNA3C) proved to target 24 regions, 3 of them 115 regions, and 2 of them 136 regions.